Key Points:
- Postural orthostatic tachycardia syndrome (POTS) affects nearly one-third of individuals with Long COVID, causing debilitating orthostatic intolerance, excessive tachycardia, and reduced quality of life. Randomized trial data to guide treatment in this population are scarce.
- RECOVER-Autonomic, the largest randomized, double-blind, placebo-controlled trial in POTS, randomized 181 adults with post-COVID POTS to ivabradine or placebo for 3 months, with a factorial design also assigning participants to coordinated nonpharmacologic care or usual care.
- Ivabradine did not significantly improve the primary endpoint of patient-reported orthostatic intolerance compared to placebo, but did significantly reduced the heart rate change from supine to standing. In a prespecified factorial analysis, ivabradine combined with coordinated care significantly improved orthostatic intolerance symptoms compared to placebo (p for interaction = 0.004).
- These findings suggest that heart rate lowering alone may be insufficient to improve symptoms in this multisystemic condition, but ivabradine combined with a structured nonpharmacologic care program may provide clinical benefit for patients with post-COVID POTS.
Postural orthostatic tachycardia syndrome (POTS) is a complex, multisystem disorder characterized by orthostatic intolerance and excessive tachycardia upon standing. Nearly 1 in 3 individuals with post-acute sequelae of SARS-CoV-2 infection, commonly known as Long COVID, develop POTS, often resulting in substantial functional impairment and reduced quality of life. Despite the growing prevalence of this condition, there are very few trials evaluating treatments for post-COVID POTS. Ivabradine, a selective inhibitor of the sinoatrial node funny current, lowers heart rate without reducing blood pressure, making it a mechanistically attractive option for this condition.
On March 29th, 2026, the results of “Impact of Ivabradine on Orthostatic Intolerance, Quality of Life and Heart Rate in Post-COVID Postural Orthostatic Tachycardia Syndrome: Results from the RECOVER-Autonomic Trial” were presented at the American College of Cardiology Scientific Sessions (ACC.26) in New Orleans, LA. The purpose of this NIH-funded trial was to determine whether ivabradine improves symptoms and quality of life in adults with post-COVID POTS.
RECOVER-Autonomic was a randomized, double-blind, placebo-controlled platform trial conducted at 40 sites across the United States [NCT06305780]. Adults with autonomic dysfunction symptoms persisting at least 12 weeks after acute COVID-19, a COMPASS-31 score >20, and confirmed POTS (heart rate increase ≥30 bpm on active stand or on tilt table test without orthostatic hypotension) were randomized in a 1:1:1:1 factorial design to ivabradine plus coordinated care, ivabradine plus usual care, placebo plus coordinated care, or placebo plus usual care for 3 months, followed by 3 months of observation. The coordinated care intervention included a high-salt diet, increased fluid intake, compression garment use, physical activity recommendations, weekly self-monitoring logs, and weekly phone calls with a care coordinator. The primary endpoint was the change in the Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to 3 months. The primary comparison was ivabradine versus placebo. Secondary endpoints included changes in heart rate during the active stand test, 6-minute walk distance, and other types of symptom scores.
Overall, 86 patients were randomized to ivabradine and 95 to placebo. The median age was 37 years, 85% were female, and 72% were White. At baseline, the mean OHQ composite score was approximately 6.0 (reflecting moderate to severe orthostatic symptoms), the mean supine heart rate was ~72 bpm, and the mean standing heart rate was ~108 bpm, with a mean heart rate increase from supine to standing of ~37 bpm. Study completion was high at 87.8% and similar across groups.
At 3 months, ivabradine did not significantly improve the primary endpoint of OHQ composite score compared to placebo (change of −1.4 vs. −1.1; adjusted between-group difference −0.14 [95% CI: −0.72 to 0.43]; p=0.63). Among secondary endpoints, ivabradine significantly reduced the change in heart rate from supine to standing compared to placebo (−13.6 vs. −11.0 bpm; adjusted between-group difference −3.95 [95% CI: −6.78 to −1.12]; p=0.007). No significant differences were observed in the Malmo POTS Symptom Score, COMPASS-31, 6-minute walk distance, or PROMIS Physical Function T-score.
Notably, in a prespecified factorial analysis, the effect of ivabradine on the OHQ differed significantly according to assignment to coordinated versus usual nonpharmacologic care (p for interaction = 0.004). Among participants assigned to coordinated care, ivabradine was associated with a significantly lower OHQ score compared to placebo (adjusted between-group difference −1.03 [95% CI: −1.83 to −0.23]), whereas among those assigned to usual care, there was no improvement with ivabradine (0.72 [95% CI: −0.09 to 1.52]).
Limitations include the relatively short 3-month treatment duration, the predominantly female and White study population, and the challenges inherent in studying a multisystemic condition with fluctuating symptoms using a single patient-reported outcome measure.
Pam R. Taub, MD, FACC, Professor of Medicine at UC San Diego, concluded: “Ivabradine lowers heart rate, but in patients with Long COVID POTS, heart rate lowering alone may be insufficient to improve symptoms in this multisystemic condition. Ivabradine, along with coordinated care, may have clinical benefit. There may be certain phenotypes of patients who would benefit from ivabradine. The natural history of Long COVID POTS is poorly understood, characterized by symptom fluctuation, and better clinical endpoints are needed to assess the impacts of intervention.”